Short Interest in RedHill Biopharma Ltd. (NASDAQ:RDHL) Rises By 486.2%

RedHill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 34,000 shares, a growth of 486.2% from the February 13th total of 5,800 shares. Based on an average daily volume of 54,100 shares, the days-to-cover ratio is presently 0.6 days. Approximately 2.7% of the shares of the company are short sold.

RedHill Biopharma Stock Up 0.5 %

Shares of NASDAQ:RDHL traded up $0.02 during midday trading on Wednesday, reaching $2.81. The company’s stock had a trading volume of 630,276 shares, compared to its average volume of 106,286. The stock has a fifty day moving average of $5.28 and a 200 day moving average of $7.14. RedHill Biopharma has a twelve month low of $2.58 and a twelve month high of $20.28.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of RedHill Biopharma in a report on Wednesday, March 5th. They issued a “hold” rating on the stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC acquired a new position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned 0.40% of RedHill Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.20% of the company’s stock.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.